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ABSTRACT: A peptide-type covalent binder for a target protein was obtained by 
combinatorial screening of fluoroprobe-conjugated peptide libraries on bacteriophage T7. 
The solvatochromic fluoroprobe works as a bait during the affinity selection process of 
phage display. To obtain the targeted covalent binder, the bait in the selected consensus 
peptide was altered into a reactive warhead possessing a sulfonyl fluoride. The reaction 
efficiency and site / position specificity of the covalent conjugation between the binder 
and the target protein were evaluated by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS), and rationalized by a protein-ligand docking simulation.  
 
■ INTRODUCTION  
In contrast to conventional medicines, targeted covalent drugs can form 
permanent bonds to target proteins and eternally deactivate them.1-5 This prolonged 
duration of inhibition6 would reduce dose frequency of drugs and improve quality-of-life 
of patients.7, 8 The covalent drugs should be required to possess high target selectivity 
and less off-target reactions,7, 9 to reduce irreversible side effects (i.e., toxicity).8, 10 To 
retain maximum target selectivity with minimal off-target reactivity,10 numerous efforts 
for rational designing of novel covalent drugs have been paid by way of, for example, 
computational methods,3, 11 fragment-based drug discovery,12 and covalent tethering.13 
In many cases, optimizing and chemical synthesis of such ideal covalent drugs 
require additional time and steps. Moreover, if three-dimensional structures of target 
proteins are not well-known, the structure-based drug development will be hindered. 
Currently, the development should be performed by limited numbers of sophisticated 
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methodologies (e.g., chemoproteomics-based one14, 15), and alternative general principles 
for obtaining target covalent binders are requested.  
 Contrary to the rational designing, expanded combinatorial screening16-19 of 
such targeted covalent binders would be an alternative way to solve these problems. 
Indeed, screening of the covalent binders from DNA-encoded chemical libraries has been 
successfully reported.20 For the screenings, displayed-peptide libraries would be also 
attractive mainly because the library diversity is large (up to ~1012 and ~1014 for phage 
and mRNA display, respectively18) and preparation of the library is fairly easy,21 
compared with the chemical ones. However, to the best of our knowledge, there are no 
reports to obtain targeted covalent binders from the displayed randomized peptide, 
presumably because 1) the introduction method of warhead (i.e., reactive group) into the 
displayed peptides with vast diversity is limited, and 2) exclusive enrichment of the 
targeted covalent binders from the vast library seems difficult; the warhead in target-
unrelated peptides could unfavorably conjugate to the target protein during biopanning 
process (Fig. S1). 
 To avoid the latter problem of unnecessary side reactions, here we take a 
detoured selection strategy to obtain a peptide-type covalent binder possessing target 
specificity (Fig. 1). First, we introduce several solvatochromic bait fragments, instead of 
the warhead, to designated cysteine on T7 phage-displayed library peptides22 via the 
gp10 based-thioetherification (10BASEd-T).23, 24 Second, we obtain targeted non-covalent 
binders from each bait-conjugated peptide library. Third, when a consensus peptide 
sequence around the designated cysteine appears, no matter what kind of bait fragment 
is used, we alter the bait in the consensus peptide into a different-structured warhead, 
to obtain the targeted covalent binder. 
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Fig. 1. Targeted covalent binders selected by combinatorial screening of bait fragment-
conjugated peptide library on bacteriophage T7, followed by an alteration to a reactive 
warhead possessing sulfonyl fluoride. The chemical structures of different 
solvatochromic bait fragments (i.e., Prodan, 4-DMN, and DBD), as well as that of an 
altered warhead, are shown in dashed inset. (A) Specific introductions of different 
solvatochromic bait fragments into a designated cysteine on displaying library peptides 
on a capsid protein (gp10) of bacteriophage T7 were performed. This gp10-based 
thioetherification (10BASEd-T) was carried out without side reactions or loss of phage 
infectivity. (B) From each bait-conjugated peptide library, target (i.e., GST) binders were 
selected by biopanning. Then, the peptide sequences were analyzed via a next generation 
sequencer (NGS), and consensus sequences for every-bait-conjugated peptide around the 
designated cysteine was determined. For each bait-conjugated peptide, solvatochromic 
fluorescence-change upon GST-binding was also confirmed. (C) To obtain the targeted 
covalent binder, the bait fragments in the consensus peptide was altered into the 
warhead. The covalent binder was mixed with the target protein, and the modified 
position on the target was analyzed by LC-MS/MS. 
 
■ RESULTS AND DISCUSSION  
As a model target protein, we chose glutathione S-transferase (GST) because 
rationally-designed covalent GST binders in which a warhead is conjugated with 
artificial reporter tags25 or a natural ligand (i.e., glutathione)26 have been reported; their 
structure information as well as conjugation efficiency upon GST binding could be easily 
compared with our combinatorially-screened binder. For the bait fragments with 
different shapes, we have chosen several small or middle-sized solvatochromic 
fluorophores with neutral charge,22, 27 so that we would sense when the bait could be 
buried deeply into a pocket of the target protein through hydrophobic interaction (Fig. 
1). These fragments were independently reacted with a designated cysteine on a T7-
displayed randomized peptide library, and three rounds of biopanning were performed 
against biotinylated-GST.22 After the selection process, amino-acid sequences of the 
polyclonal binders possessing each fragment were directly analyzed by a next generation 
sequencer (NGS). As shown in Table 1, common consensus sequences for all of these 
three bait fragments were obtained. In the common consensus peptides, structural 
flexibility of the fragment which is dangling on the designated cysteine seemed to be 
widely allowed. Among them, we chose ZC*DGZ sequence (highlighted in blue, Table 1) 
for further experiments, because it does not contain any wobble amino acids (i.e., X). 
 
4 
 
 
Table 1. GST-specific binders selected after 3 rounds of biopanning. C*, Z, and X 
represent bait-fragment conjugated cysteine, hydrophobic amino acids, and any amino 
acids, respectively. The consensus sequences from each bait fragment were summarized 
by frequency of the top 100 occurrences obtained from NGS data analysis. The bold letter 
stands for common consensus sequence for all of the different-bait-conjugated peptides. 
The detailed sequences with the abundance ratio for each monoclone of ZC*DGZ were 
presented in Table S1.  
 
(A) C*: DBD-conjugated cysteine 
Consensus sequence Frequency 
ZC*DGZ 20/100 
ZZC*DGZ 12/100 
C*XDGZ 10/100 
 
(B) C*: 4-DMN-conjugated cysteine 
Consensus sequence Frequency 
ZC*DGZ 9/100 
ZXYC*XDGZ 2/100 
 
(C) C*: Prodan-conjugated cysteine 
Consensus sequence Frequency 
C*XXXDDGZ 10/100 
ZC*DDGZ 8/100 
ZC*DGZ 7/100 
C*XDDGZ 6/100 
C*XXXXDGZ 6/100 
C*XDGZ 5/100 
C*XXXDGZ 4/100 
 
 
Next, a representative common peptide whose sequence is LNYCDGW (the 
common consensus sequence is underlined) was synthesized, because it is one of the most 
abundant sequences obtained from six rounds of biopanning against GST using 4-DMN-
conjugated randomized peptide library.22 Then, its sulfhydryl group was conjugated with 
all of the bait fragments independently. When each bait-conjugated peptide was mixed 
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with GST, a remarkable solvatochromic fluorescence change was observed (Fig. S2). This 
means that the microenvironment around the bait changed after the addition of GST, 
and most probably, all of the bait fragments were located inside of the hydrophobic pocket 
of GST, no matter what kind of the chemical structures were used. 
Encouraged by the solvatochromic fluorescence, next we altered the bait 
structures to a reactive warhead, and target-protein specific covalent binding of the 
altered peptide was evaluated. We chemically synthesized a targeted covalent-binder 
peptide whose sequence is Fam–GGLNYC*DGW (Fig. 2A; Fam, GG, and C* represent 
carboxyfluorescein, glycylglycine spacer, and warhead-conjugated cysteine, respectively), 
and its appropriate covalent conjugation with GST was confirmed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE; Fig. 2B). As the warhead, we 
chose sulfonyl fluoride (SO2F),25, 26, 28 because the reactive group possesses an exquisite 
balance of aqueous stability and moderate reactivity toward nucleophilic amino acids 
(i.e., serine, threonine, lysine, tyrosine, cysteine, and histidine residues in the target 
protein).29, 30 When 4-(2-bromoacetyl)benzene-1-sulfonyl fluoride was reacted with the 
sulfhydryl group of the precursor peptide, complex reaction products were formed and 
we could not separate the expected covalent binder peptide. In contrast, when 
ethenesulfonyl fluoride26 was reacted, only a single component of the covalent binder 
peptide was successfully obtained (Fig. 2A; for details, see Fig. S3). The covalent-binder 
peptide was mixed with GST in the presence of serum proteins, and the reaction mixture 
was analyzed by SDS-PAGE followed by fluorescence imaging / coomassie brilliant blue 
(CBB) staining. An intense fluorescent band could be seen at an appropriate molecular 
weight (ca. 29 kDa) of the peptide-fused GST (Fig. 2B). This means that we could 
successfully confirm the covalent-binding property, as well as the GST specificity, of the 
peptide. 
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Fig. 2. (A) Synthesis of a targeted covalent-binder peptide; Fam stands for a fluorophore 
at the N-terminus. (B) Specific conjugation between the covalent binder and GST, 
confirmed by 15% SDS-PAGE / fluorescence imaging. Whole proteins were visualized by 
CBB staining (left panel), and a protein conjugated with the covalent binder was 
visualized by fluorescence in the same gel (right). Blue arrow represents the band of the 
target protein (i.e., GST). At this stage, the crosslinking reaction yield was less than 
few% and the structural information could not be obtained by LC-MS/MS analysis. 
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To avoid unfavourable steric hindrance upon target binding and non-specific 
hydrophobic interactions arising from the fluorophore, LNYC*DGW peptide without 
Fam–GG was once again synthesized. The chemical structure of the covalent binder was 
tentatively identified by combination of 1H NMR, MS, and MS/MS analyses (Fig. S4), 
and favorably, the warhead did not react with its intrinsic tyrosine residue. Then, the 
reaction efficiency and site / position specificity of the covalent conjugation between the 
Fam-eliminated covalent binder and GST were evaluated as the following. First, the 
covalent binder and GST were reacted, and SDS-PAGE was performed. Then, the GST 
band in the gel was excised and digested with trypsin. The resulting peptide fragments 
were analyzed by LC-MS/MS. An intense absorbance in the chromatogram was newly 
detected after the conjugation (Fig. 3A), and it was identified as the GST-conjugated 
covalent binder by MS (Fig. 3B) and tandem mass spectroscopy (Fig. 3C). The 
crosslinking site was determined to be the glutathione binding pocket; the crosslinked 
amino acid was a tyrosine which was located at the 111th position from the N-terminus. 
This position was exactly the same when the rationally-designed binders25, 26 were 
covalently conjugated (also see Fig. S5). From measurement of the abundance ratio of 
unreacted peptide fragment possessing the 111th tyrosine, the crosslinking reaction yield 
of our covalent binder was estimated to be 37%, which was much superior to that of the 
rationally-designed one (Fig. S6). 
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Fig. 3. Identification of fragments derived from the covalent-binder-conjugated GST 
peptide by LC-MS/MS analysis. (A) LC profiles of trypsin-digested peptide fragments 
derived from modified- and unmodified-GST. The absorbance above 270 nm was 
measured. (B) MS and (C) MS/MS spectra of the newly appeared peak (arrowed in Fig. 
3A).  All the detected fragments were consistent with theoretical m/z values of the 
represented structure. The peptide fragment of IAYSK was derived from a constituent of 
the glutathione binding pocket of GST protein. Y* means conjugated tyrosine. 
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Finally, the conjugation of the covalent binder was rationalized by a protein-
ligand docking simulation using MolDesk Basic / myPresto.31 Thirty separate poses 
resulted in docking to the glutathione binding pocket of GST with free energy in the 
range -12.4 to -7.83 kcal/mol. As shown in Fig. 4, the docking model of the lowest energy 
suggested that the warhead was buried deep inside the hydrophobic region of the 
glutathione-binding pocket and located very close to the conjugated tyrosine of the 111th 
position. The geometry of the altered warhead is in good agreement with the 
solvatochromic fluorescence change of the bait-conjugated peptide upon GST binding 
(Fig. S2). We speculate this proximity between the warhead and the 111th tyrosine caused 
the site- and position-specific efficient crosslinking. In contrast, the lowest docking model 
of the rationally-designed one suggested that the warhead was located outside of the 
pocket (Fig. S7), which might result in the insufficient conjugation with the 111th tyrosine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Molecular docking simulation of the covalent binder (shown as a stick) to GST 
(PDB ID: 1UA5) using sievgene of myPresto; the best docking model with a lowest 
binding energy of -12.4 kcal/mol was presented. Fluorine atom in the warhead and 
conjugated tyrosine in GST were colored in cyan and dark red, respectively. GST was 
shown as a cartoon with side chains as a line description. 
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■ CONCLUSIONS  
In conclusion, we have established a precise and efficient conjugation method 
between a hydrophobic pocket of a target protein and a targeted peptide. The peptide as 
a covalent binder has been obtained by combinatorial screening of a bait fragment-
conjugated peptide library on phage, followed by an alteration of the bait to a reactive 
warhead. Although the example shown here is not completely representative, the choice 
of GST enables us to rationalize the target binding retrospectively by using a 
computational model based on the crystal structure. Current limitation of this 
methodology seems that the bait-conjugated peptide tend to bind to a promiscuous large 
binding pocket.  Nevertheless, we believe the non-reactive bait-alteration concept will 
be useful in general for the future, to discover covalent drugs made of peptide as 
antibody-drug substitutes, especially aimed for cell-surface receptors. 
 
■ MATERIALS AND METHODS   
 
Biopanning against GST by using bait fragment-conjugated peptide library. Synthesis of 
each bait-conjugated peptide library on phage and biopanning against GST was 
performed as described previously.22 In brief, approximately 1.0 × 1011 pfu of T7Select10 
library (-S-G-G-G-X3-C-X5-7-C-X3; X represents any randomized amino acid) was 
modified with bromoacetamide (BA)-conjugated bait fragment via the 10BASEd-T. After 
modification, the T7 phage library was dissolved in selection buffer (PBS supplemented 
with 0.1% v/v TritonX-100). To remove non-specific binders (e.g., beads and streptavidin 
binders), the modified T7 phage library was pre-incubated with streptavidin-coupled 
beads for 16 hours at 4 °C, and then the supernatant was further incubated with the 
GST-immobilized beads for 15 hours. The latter beads were washed three times for 14 
minutes in total with 0.2 mL of the selection buffer. The entire binding and washing 
processes were performed using an automated machine (Target Angler 8, Tamagawa 
Seiki, Japan). GST-bound phage was directly infected and amplified with E. coli 
BLT5403 strain. Increasing stringent conditions such as shortening the binding time 
(e.g., 400 min at the final round) and increasing the washing frequency / time (up to five 
times / 70 min in total at the final round), were applied stepwise to each round. After 3 
rounds of biopanning, a mixture of T7 phage polyclones was subjected to a next 
generation sequencer (NGS), to obtain the common consensus sequence. 
 
Synthesis of the bait-conjugated peptides and confirmation of their solvatochromic 
fluorescence-change upon GST-binding. Each bait-conjugated peptide possessing 
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LNYCDGW sequence was synthesized by reaction of each BA-conjugated bait fragment 
independently, according to the reported procedure.27 Then, each bait-conjugated peptide 
(0.07 mM) was mixed with equal molar of GST or streptavidin in PBS. It was incubated 
for 10 minutes at room temperature, and fluorescence spectrum was measured (Fig. S2). 
 
Conjugation between GST and covalent binders:  
(A) Preliminary covalent modification at the glutathione-binding pocket using a reported 
covalent binder. A rationally-designed covalent binder (abbreviated as E’C*G), which is 
known to irreversibly bind to the glutathione-binding pocket of human GST, was 
synthesized and identified according to the reported procedure26 in combination with 
MS/MS analysis (Fig. S5B). The binder (5.2 mM) was mixed with S. japonicum GST (2.7 
mM) in 20 mM phosphate buffer (pH 7.5), and incubated for 21 hours at 37 °C in the 
dark. It was mixed with 1×sample buffer, denatured at 95 °C, separated by 15% SDS-
PAGE followed by trypsinization / LC-MS/MS analysis. The reported covalent binder 
successfully conjugated to a tyrosine located at deep inside the glutathione binding 
pocket of S. japonicum GST (Fig. S5C). 
(B) Specific conjugation between combinatorially-screened covalent binder and GST 
confirmed by SDS-PAGE / fluorescence imaging. Fluorescent peptide (Fam–
GGLNYCDGW, 0.01 M) was dissolved in 20 mM phosphate buffer (pH 7.4) / 10% 
acetonitrile, and reacted with ethenesulfonyl fluoride (ESF, 0.1 M) or 4-(2-
bromoacetyl)benzenesulfony fluoride (BBSF, 5 mM) in the presence of neutralized tris(2-
carboxyethyl)phosphine (TCEP, 2 mM). The mixture was reacted for more than 4 hours 
at room temperature in the dark with vigorous shaking, and the reaction was monitored 
by HPLC (Fig. S3). Only the ESF-conjugated covalent binder could be purified by 
reverse-phase HPLC, and it was used for further experiments. The purified covalent 
binder (0.10 mM) was mixed with GST (0.31 mM) in phosphate buffer (pH 7.5) in the 
presence of 40% (v/v) human serum (Sigma, H4522), and incubated for 21 hours at 37 °C 
in the dark. It was mixed with 1×sample buffer, denatured at 95 °C, and separated by 
15% SDS-PAGE. The binder-conjugated proteins were detected by fluorescence imaging, 
and whole proteins were visualized by CBB staining (Fig. 2B).  
(C) Detailed identification of the conjugated site / position on GST after the reaction with 
combinatorially-screened covalent binder. Peptide (LNYCDGW, 0.24 M) was dissolved in 
20 mM phosphate buffer (pH 7.4) / 10% acetonitrile, and reacted with ESF (0.26 M) in 
the presence of neutralized tris(2-carboxyethyl)phosphine (TCEP, 2 mM). The mixture 
was reacted for more than 4 hours at room temperature in the dark with vigorous 
shaking, and purified by reverse-phase HPLC (yield 60%), and identified with 1H NMR, 
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MS, and MS/MS analyses (Fig. S4). Covalent conjugation reaction with GST, and SDS-
PAGE followed by trypsinization / LC-MS/MS analysis were performed under the same 
conditions described above (A), except using the combinatorially-screened covalent 
binder (i.e., LNYC*DGW) instead of the glutathione derivative (i.e., E’C*G). 
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